MRD1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4618-4627

  Tada, Y ^a   Wada, M ^a   Kuroiwa, K ^a   Kinugawa, N ^a   Harada, T ^a   Nagayama, J ^a   Nakagawa, M ^a   Naito, S ^a   Kuwano, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE; RIBONUCLEASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; DISEASE MARKER; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TUMOR RECURRENCE; BIOSYNTHESIS; BLADDER TUMOR; CPG ISLAND; DNA METHYLATION; GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, SOUTHERN; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; RNA, MESSENGER; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0034351878     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Multidrug resistance mediated by the ATP- binding cassette transporter protein MRP
2. Biochemistry of multidrug resistance mediated by the multidrug transporter
3. Mechanism of multidrug resistance
4. Genes amplified and overexpressed in human multidrug-resistant cell lines
5. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression
6. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
7. Multidrug resistance-associated protein subfamily transporters and drug resistance
8. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
9. Expression of a multidrug-resistance gene in human tumors and tissues
10. Expression of a multidrug resistance gene in human cancers
11. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
12. Gene rearrangement: A novel mechanism for MDR-1 gene activation
13. Alu-associated interstitial deletions and chromosomal re-arrangement in 2 human multidrug-resistant cell lines
14. Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D
15. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene
16. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression
17. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma
18. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?
19. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer
20. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells
21. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
22. Hypomethylation status of CpG sites at the promoter region and over-expression of the human MDR1 gene in acute myeloid leukemias
23. Evaluation of multiple drug resistance in human bladder cancer cell lines
24. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines
25. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM
26. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer
27. Establishment and characterization of two human bladder cancer cell lines
28. Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay
29. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression
30. BMDP program for piecewise linear regression
31. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: A randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone
32. Alterations in DNA methylation: A fundamental aspect of neoplasia
33. Roles of cell division and gene transcription in the methylation of CpG islands
34. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island
35. An alternative promoter in the mouse major histocompatibility complex class II I-Aβ gene: Implications for the origin of CpG islands
36. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation
37. How does DNA methylation repress transcription?